AL BENSON MD NPI 1891761532

NPI Details

Al Benson, MD is a medical oncology internal medicine in Chicago, IL with 50 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. Al Benson, MD NPI is 1891761532. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: STATE UNIVERSITY OF NEW YORK AT BUFFALO SCHOOL OF MEDICINE
Graduation Year:1976

The provider's business location address is:

675 N SAINT CLAIR ST
SUITE 100
CHICAGO, IL
ZIP 60611-975
Phone: (312) 695-0990
Fax: (312) 695-6189

The NPI 1891761532 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, carfilzomib, 1 mg (HCPCS:J9047)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)

The enumeration date for this NPI number is 2/23/2006 and was last updated on 7/16/2009.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.